

Erdafitinib

Catalog No: tcsc4988



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1346242-81-6

Formula:

$C_{25}H_{30}N_6O_2$

Pathway:

Protein Tyrosine Kinase/RTK

Target:

FGFR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 33 mg/mL (73.90 mM)

Alternative Names:

JNJ-42756493

Observed Molecular Weight:

446.54


Product Description

Erdafitinib (JNJ-42756493) is a potent and orally available **FGFR** family inhibitor; inhibits FGFR1-4 with **IC₅₀** values of 1.2, 2.5, 3.0 and 5.7nM, respectively.

IC50 & Target: IC50: 1.2 nM (FGFR1), 2.5 nM (FGFR2), 3.0 nM (FGFR3)and 5.7 nM (FGFR4)^[1]

In Vitro: Erdafitinib inhibits the tyrosine kinase activities of FGFR1-4 in time-resolved fluorescence assays with IC₅₀ values of 1.2, 2.5, 3.0 and 5.7 nM, respectively. The closely related VEGFR2 kinase is less potently inhibited (30-fold less potent compared to FGFR1) by erdafitinib, with an IC₅₀ value of 36.8 nM. JNJ-42756493 binds FGFR1, 3, 4, and 2 with K_d values of 0.24, 1.1, 1.4 and 2.2 nM, respectively. The K_d value for VEGFR2 is higher at 6.6 nM. JNJ-42756493 inhibits proliferation of FGFR1, 3, and 4 expressing cells with IC₅₀ values of 22.1, 13.2, and 25nM, respectively^[1].

In Vivo: In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, Erdafitinib administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!